摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1'-C-methyladenosine | 16848-12-7

中文名称
——
中文别名
——
英文名称
1'-C-methyladenosine
英文别名
6-amino-9-(1-deoxy-β-D-psicofuranosyl)purine;(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-methyloxolane-3,4-diol
1'-C-methyladenosine化学式
CAS
16848-12-7
化学式
C11H15N5O4
mdl
——
分子量
281.271
InChiKey
MXYRZDAGKTVQIL-IOSLPCCCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.7
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    140
  • 氢给体数:
    4
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2-O-acetyl-6-O-benzyl-3,4-O-benzylidene-1-deoxy-D-psicofuranose 在 10percent Pd/C 、 ammonium formate 、 二氯乙基铝 作用下, 以 甲醇甲苯乙腈 为溶剂, 反应 8.0h, 生成 1'-C-methyladenosine
    参考文献:
    名称:
    Ribose-Modified Nucleosides as Ligands for Adenosine Receptors:  Synthesis, Conformational Analysis, and Biological Evaluation of 1‘-C-Methyl Adenosine Analogues
    摘要:
    1'-C-Methyl analogues of adenosine and selective adenosine A, receptor agonists, such as N-[(1R)-1-methyl-2-phenylethyl]adenosine ((R)-PIA) and N-6-cyclopentyladenosine, were synthesized to further investigate the subdomain that binds the ribose moiety. Binding affinities of these new compounds at A(1) and A(2A) receptors in rat brain membranes and at A(3) in rat testis membranes were determined and compared. It was found that the 1'-C-methyl modification in adenosine resulted in a decrease of affinity, particularly at A(1) and A(2A) receptors. When this modification was combined with N-6 substitutions with groups that induce high potency and selectivity at A(3) receptors, the high affinity was in part restored and the selectivity was increased. The most potent compound proved to be the V-C-methyl analogue of (R)-PIA with a K-i of 23 nM for the displacement of [H-3]CHA binding from rat brain A(1) receptors and a >435-fold selectivity over A(2A) receptors. In functional assays, these compounds inhibited forskolin-stimulated adenylate cyclase with IC50 values ranging from 0.065 to 3.4 muM, acting as full agonists. Conformational analysis based on vicinal proton-proton J-coupling constants and molecular mechanics calculations using the MM2 force field proved that the methyl group on C1' in adenosine has a pronounced impact on the furanose conformation by driving its conformational equilibrium toward the north, gamma+, syn form.
    DOI:
    10.1021/jm0102755
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE L'HÉPATITE C
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2012141704A1
    公开(公告)日:2012-10-18
    The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    该披露提供了公式I的化合物,包括药用可接受的盐,以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒(HCV)具有活性,并可能对感染HCV的人有用。
  • Hepatitis C Virus Inhibitors
    申请人:Belema Makonen
    公开号:US20100080772A1
    公开(公告)日:2010-04-01
    The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    本公开涉及化合物、组合物和治疗丙型肝炎病毒(HCV)感染的方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
  • [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2011059850A1
    公开(公告)日:2011-05-19
    The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.
    本公开涉及制备用于治疗丙型肝炎病毒(HCV)感染的化合物的方法。
  • [EN] NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS<br/>[FR] NOUVEAUX RÉACTIFS À BASE DE PHOSPHORE (V), LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION DANS LA FABRICATION DE COMPOSÉS ORGANOPHOSHOREUX (V) STÉRÉODÉFINIS
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2019200273A1
    公开(公告)日:2019-10-17
    The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
    本发明涉及新型(V)(P(V))试剂,其制备方法以及利用这种新型试剂制备有机(V)化合物的方法。
  • [EN] COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT D'ADMINISTRER DES AGENTS THÉRAPEUTIQUES
    申请人:MODERNATX INC
    公开号:WO2017099823A1
    公开(公告)日:2017-06-15
    This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    这项披露提供了改进的基于脂质的组合物,包括脂质纳米粒子组合物,以及它们用于体内传递药剂的方法,包括核酸和蛋白质。这些组合物不受加速血清清除的影响,并且它们在体内具有改进的毒性特性。
查看更多